Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | SI | P14410 | 5/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047429 | 0.82 | MEN1 (0.59) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL3370820 | 0.82 | MEN1 (0.59) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL1893849 | 0.82 | MEN1 (0.59) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL4771578 | 0.81 | NR4A2 (0.53) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL4766917 | 0.81 | NR4A2 (0.53) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL9688080 | 0.81 | NR4A2 (0.53) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL719008 | 0.81 | MAPT (0.57) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL6283244 | 0.81 | GPR84 (0.59) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL1349263 | 0.79 | MEN1 (0.56) | MEN1KMT2AMAPTPKMGPR84 | |
| SCHEMBL30518932 | 0.79 | MEN1 (0.56) | MEN1KMT2AMAPTPKMGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009093013-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2054417-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB Pharma S.A. (BE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | MEN1 1220/4885KMT2A 2093/4885MAPT 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.